Recently, YaoSu Biotechnology has proudly announced the successful conclusion of its Series A funding round, having amassed more than 200 million yuan. Notably, Legend Capital, an existing investor, has decided to further bolster its investment. The capital raised in this round will be strategically allocated towards the construction of cutting-edge bio-intelligent infrastructure, the acceleration of AI platform development and collaboration, as well as the establishment of a sophisticated 3D bio-intelligent system. YaoSu Biotechnology, a pioneering AI for 3D Biology platform company, leverages organ-on-a-chip technology as its core focus. It has forged partnerships with numerous industry-leading enterprises, witnessed rapid business expansion, and successfully deployed key application scenarios.

In terms of regulatory milestones, its organ-on-a-chip platform has embarked on the FDA review journey, with the anticipation of securing scientific endorsement and qualification. Post-financing, YaoSu Biotechnology is poised to ramp up investment in enhancing its AI team, propelling the industrial integration of automated experimental platforms, and constructing a comprehensive knowledge graph. The company's founder has expressed a commitment to fortifying technological barriers and collaborating closely with partners to propel the widespread adoption of '3D bio-intelligence.' Legend Capital continues to harbor a positive outlook on YaoSu Biotechnology's platform prowess and its potential to unlock significant commercial value.